secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)
CIK:        0001500198
Form:       8-K
Filed at:   2024-09-13T23:59:59+00:00
Accession:  0001213900-24-078584
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroOne amends CEO & three other execs' change-in-control severance benefits
-----------------------------------------------------------------------------

- CEO Rosa: 2.0x base salary + 2.0x target bonus lump sum, full equity vest, 24-month COBRA upon qualifying termination.
- CFO McClurg, COO Volker, CTO Mertens: 1.25x base + 1.25x bonus lump sum, full vest, 15-month COBRA.
- Amendments effective Sep 9, 2024; apply to terminations within 12 months after or 3 months before a change in control.
- Benefit conditioned on signing a release and ongoing compliance; all other employment terms unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1500198/000121390024078584/0001213900-24-078584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1500198/000121390024078584/ea0214149-8k_neuroone.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-078584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer